Relapsed and/or Refractory Multiple Myeloma Clinical Trials in Hangzhou, Zhejiang
2 recruitingHangzhou, Zhejiang, China
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Relapsed and/or Refractory Multiple Myeloma
OriCell Therapeutics Co., Ltd.83 enrolled5 locationsNCT06182696
Recruiting
Phase 1Phase 2
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Relapsed and/or Refractory Multiple Myeloma
Beijing InnoCare Pharma Tech Co., Ltd.80 enrolled6 locationsNCT05719701